Belizatinib 是可口服的ALK 和 TRKA、TRKB、TRKC 双重抑制剂，对野生型重组 ALK 的IC50值为0.7?nM。

Belizatinib is an effective, oral and dual inhibitor of ALK (IC50: 0.7 nM, wild-type recombinant ALK) and TRKA, TRKB, and TRKC.

In the Clinicalal trials, Belizatinib has antitumor activity.

In mouse models, Belizatinib can continuously and effectively inhibit ALK-dependent tumor growth.

1357920-84-3

C33H44FN5O3

577.75

TSR-011

DMSO:300 mg/mL
Powder: -20°C for 3 years
In solvent: -80°C for 2 years